Diasorin announces 510(k) clearance for LIAISON PLEX Gram-Positive Blood Culture Assay
Diasorin announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LIAISON PLEX Gram-Positive Blood Culture Assay, the final syndromic blood culture panel for the microbiological diagnosis of bloodstream infections on the LIAISON PLEX.
Diasorin has now received 510(k) clearance from the FDA for both the respiratory and the blood culture portfolio on the LIAISON PLEX.
The selection of the test panel for diagnosing bloodstream infections takes place as the next step following culture and Gram staining, which are performed by laboratories in cases of suspected bloodstream infection. Based on the Gram stain result, the laboratory can rapidly identify the type of pathogen responsible (yeasts, gram-positive, or gram-negative bacteria) and select the most appropriate and specific molecular panel. This targeted approach helps reduce costs compared to currently available solutions, which instead test for a wide range of pathogens regardless of the Gram stain outcome.
The LIAISON PLEX Gram-Positive Blood Culture Assay detects 17 targets (13 gram-positive bacteria and 4 relevant resistance gene targets) in under 2 hours, including Bacillus spp. and mecC, in addition to the targets currently found on the VERIGENE Gram-Positive Blood Culture Test, providing clinicians with the ability to make rapid and targeted treatment decisions.
The assay features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions, thereby minimizing the risk of false positives.
